BAGSVAERD, Denmark, Feb. 9, 2007 (PRIME NEWSWIRE) -- Novo Nordisk A/S has filed its Annual Report 2006 on Form 20-F for the financial year 2006 with the U.S. Securities and Exchange Commission (SEC), incorporating by reference the Novo Nordisk A/S Annual Report 2006. The reports are available on the SEC's website, www.sec.gov as well as at: novonordisk.com -- Investors -- Download centre.
Shareholders and ADR holders may receive a hard copy of the annual report free of charge by calling (+1) 609 919 7937 or by sending a request via e-mail to cqfr@novonordisk.com. When e-mailing, please include the exact mailing address, postal code and requested document(s).
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO.' For more information, visit novonordisk.com.